UCSD Medical Center investigators are enrolling patients in a Phase 2 clinical trial of MYDICAR®, a new gene therapy for advanced heart failure.
The drug is designed to boost the efficiency of the heart by restoring a crucial heart enzyme.
UCSD cardiologist Dr. Barry H. Greenberg is principal investigator of the UCSD portion of the study, which is known as the Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID) trial.
In all, 13 centers are participating.
Dr. Greenberg is Professor of Medicine in the Division of Cardiology and director of the Advanced Heart Failure Treatment Program at UCSD Medical Center. He is the founder and current president of the Heart Failure Society of America.